| Literature DB >> 27014064 |
M Akhtar Anwar1, Sara S Al Disi1, Ali H Eid2.
Abstract
Traditional medicine has a history extending back to thousands of years, and during the intervening time, man has identified the healing properties of a very broad range of plants. Globally, the use of herbal therapies to treat and manage cardiovascular disease (CVD) is on the rise. This is the second part of our comprehensive review where we discuss the mechanisms of plants and herbs used for the treatment and management of high blood pressure. Similar to the first part, PubMed and ScienceDirect databases were utilized, and the following keywords and phrases were used as inclusion criteria: hypertension, high blood pressure, herbal medicine, complementary and alternative medicine, endothelial cells, nitric oxide (NO), vascular smooth muscle cell (VSMC) proliferation, hydrogen sulfide, nuclear factor kappa-B (NF-κB), oxidative stress, and epigenetics/epigenomics. Each of the aforementioned keywords was co-joined with plant or herb in question, and where possible with its constituent molecule(s). This part deals in particular with plants that are used, albeit less frequently, for the treatment and management of hypertension. We then discuss the interplay between herbs/prescription drugs and herbs/epigenetics in the context of this disease. The review then concludes with a recommendation for more rigorous, well-developed clinical trials to concretely determine the beneficial impact of herbs and plants on hypertension and a disease-free living.Entities:
Keywords: endothelial/vascular smooth muscle cells; epigenetics; herbal medicine; hypertension; inflammation; nitric oxide; oxidative stress
Year: 2016 PMID: 27014064 PMCID: PMC4782109 DOI: 10.3389/fphar.2016.00050
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Less commonly used antihypertensive plants with antioxidant activity.
| Scavenges ROS | 0.125 mg/ml | DPPH enzymatic assay | Builders et al., | |
| Reduces oxLDL | 0.1 mg/L | Human umbilical vein endothelial cells | Shen et al., | |
| Scavenges ROS | 10 μg/ml | Rat isolated aortic rings | Lau et al., | |
| Scavenges ROS | 4.79 μg/ml | DPPH enzymatic assay | Predes et al., | |
| Increases antioxidants | 20 mg/kg | Renovascular hypertensive rats | Zhou et al., | |
| Scavenges ROS | 0.32–200 μg/ml | DPPH enzymatic assay | Jeong et al., | |
| Reduces ROS | 50–200 μg/ml | Isoproterenol-treated cardiomyocytes | Sankar et al., | |
| Increases antioxidants | 3 g/day | Stage 1 hypertensive patients | Verma et al., | |
| Increases antioxidants | 100 mg/kg | Isoproterenol-treated rats | Bhandari et al., | |
| 50 mg/kg | High fat-fed rats | Chaudhari et al., | ||
| Increases antioxidants | 90 mg/kg | SHR | Gholitabar and Roshan, | |
| Decreases LDL cholesterol | 6 mg/kg/day | High fat-fed SHR | Lee O. H. et al., | |
| Increases antioxidants | 25–100 mg/kg/day | High salt-loaded rats | Bopda et al., | |
| Scavenges ROS | 500 μg (of the lyophilized extract in a tube) | DPPH enzymatic assay | Kaur et al., | |
| Increases antioxidants | 50, 100, and 200 mg/kg | DOCA-salt hypertensive rats | Veeramani et al., | |
| Scavenges ROS | IC50 range: 8.17–24.91 μg/ml (for different solvent-extractions) | DPPH enzymatic assay | Kaurinovic et al., | |
| Increases antioxidants | 200 mg/kg | Male Albino Wistar rats | Karuna et al., | |
| Scavenges oxidants | 0–1 mg/ml (varies for each assay) | DPPH enzymatic assay (and other oxidant scavenging assays) | Maity et al., | |
| Regulates SOD and NO | 100 and 200 mg/kg | SHR | Zhao et al., | |
| Scavenges oxidants | IC50 range: 7.90 to >200 μg/ml (for different solvent-extractions) | DPPH enzymatic assay (and other | Jin et al., | |
| Increases antioxidants | 6.25–25 mg/kg/day | 2K-1C rats | Cao et al., | |
| Decreases peroxidants | ||||
| Increases antioxidants | 30 and 90 mg/kg | SHR | Chung et al., | |
| Scavenges oxidants | IC50 range: 23–200 μg/ml (for different parameters using different solvent-extractions) | DPPH enzymatic assay | Beevi et al., | |
| Scavenges oxidants | IC50 range: 0.71 to >12 μg/ml (for different fractions) | DPPH enzymatic assay | Kosar et al., | |
| Increases antioxidants | 200 ml/day | Healthy humans | Ivanova et al., | |
| Scavenges ROS | 25–1000 mg/ml | DPPH enzymatic assay | Visavadiya et al., | |
| Inhibits LDL peroxidation | Mitochondrial fraction and human serum | |||
| Reduces iNOS and COX-2 expression | 100 μM of its active compound, tetrandrine | Human monocytic cells | Wu and Ng, | |
| Reduces production of oxidants | 25–50 μM of its active compound, tetrandrine | LPS-stimulated microglia | Xue et al., | |
| Scavenges ROS | IC50 range: 9–42 μg/ml (for different solvent-extractions) | DPPH enzymatic assay | Park et al., | |
| Reduces H2O2 | 0.240 mg/ml of the plant's total saponins | Primary VSMCs from aorta of newborn calves | Li et al., | |
| Reduces ACE | 300 mg/kg ethanolic extract, 200 mg/kg purified fraction, 10 mg/kg isoquercitrin | SHRs | Gasparotto Junior et al., | |
| Reduces ROS | 10 mg/kg | |||
| Inhibits cardiac lipid peroxidation | 60 mg/kg/day | Glucocorticoid-treated rats | Bachhav et al., | |
| Increases NO | ||||
| Scavenges oxidants | ED50 range: 34.1–63.3 μg/ml (for different compounds) | DPPH enzymatic assay | Kuo et al., |
Less commonly used antihypertensive plants with vasorelaxant activity.
| Not clear | 0.001–3 mg/ml | Rat isolated aorta | Ouedraogo et al., | |
| Ca2+ regulation | 0.01–1 mg/ml | High K+-treated rabbit aorta | Shah and Gilani, | |
| Not clear | 0.0625–2 mg/ml | Rat isolated thoracic aorta | Naseri et al., | |
| Increases eNOS expression | 400 mg/kg/day | Fructose-fed rats | Vazquez-Prieto et al., | |
| Increases NO | 100 and 300 μg/ml | DOCA-salt-induced hypertension in rats | de Moura et al., | |
| Blocks Ca2+ channels | 1–20 mg/kg | Wistar rats thoracic aortic rings | da Cunha et al., | |
| Increases NO production | 10 μg/ml | Rat isolated aortic rings | Lau et al., | |
| Not clear | 100 and 200 mg/kg/day | High fat-fed Sprague-Dawley rat thoracic aorta | Lee Y. J. et al., | |
| Increases NO | 10−5–10−3 g/ml | Rat isolated aorta | Calderone et al., | |
| Ca2+ regulation | 102–494 μg/ml | Various isolated blood vessels from rat | Kamkaew et al., | |
| Increases NO | ||||
| Opens KATP channels | 0.1–3 mg/kg/day | Rat isolated hearts | Nie et al., | |
| Blocks Ca2+ influx | 3.06 and 3.63 mg/ml | Rat isolated aorta | Ajagbonna et al., | |
| Opens KATP channels | 5, 10, and 20 mg/kg | Isolated aortic rings | Nyadjeu et al., | |
| Increases NO | 300 mg/kg/day | Isolated aortic rings | Nyadjeu et al., | |
| Increases NO bioavailability | 0.1–1 mg/ml | Rat isolated thoracic aorta | Kim et al., | |
| Relaxes vessels | ED50: | rat aorta, bovine coronary artery, canine coronary artery | Muller and Baer, | |
| Lowers blood pressure | Up to 5 μg/ml | Feline, canine, SHR and renal hypertensive rats | Lindner et al., | |
| Reduces MAP; mechanism not elucidated but likely via cAMP | 0.1–1 mg/ml; | Feline | Dubey et al., | |
| 10 mg/kg, p.o. | Normotensive rats and SHR | Dubey et al., | ||
| Decreases SBP, DBP, and MAP; mechanism not elucidated but likely via cAMP | 0.5–3 μg/kg/min infusions of forskolin | Human patients with cardiomyopathy | Baumann et al., | |
| Promotes extracellular Ca2+ influx and release of Ca2+ from intracellular stores | 0.5–5 mg/ml | Rat thoracic aortic rings | Koh et al., | |
| Increases NO | ||||
| Increases Akt, NO and eNOS | 100 and 200 mg/kg/day | High fat/cholesterol-fed rats | Choi et al., | |
| Increases NO and cGMP levels | 100 and 200 mg/kg/day | High fat/cholesterol-fed ApoE-deficient mice | Choi et al., | |
| Increases NO production | 300–1000 mg/kg; | SHR | Lessa et al., | |
| 0.1 mg/ml | Rabbit aortic rings | Tibiriçá et al., | ||
| Blocks Ca2+ channels | 2.94 mg/ml | Rat isolated aorta | Gilani et al., | |
| Ca2+ regulation | 10−4–10−7 g/ml | Rat aortic rings | Wang et al., | |
| Increases NO | ||||
| Blocks Ca2+ channels | 0.3–1 mg/ml | Rat aorta | Khan et al., | |
| Increases NO | 30 μg/ml | Rat aortic rings | Xie et al., | |
| Inhibits Ca2+ channels | 10−5–10−3 g/ml | Rat aortic rings | Hoe et al., | |
| Increases NO | 500 mg/kg | SHR | Kim et al., | |
| Opens KATP channels | 0.003 and 0.009 g/ml | Rat isolated thoracic aortic rings | Ng et al., | |
| Reduces Ca2+ influx | 10 and 100 μM | Rat isolated aortic rings | Tep-Areenan et al., | |
| Decreases defibrillation efficacy | 12.5–100 mg/kg | Porcine | Weerateerangkul et al., | |
| Decreases Ca2+ | 75–300 μg/mL | Ventricular myocytes | Weerateerangkul et al., | |
| Increases NO signaling | 1–100 μM | Rat isolated aortic rings | Tep-Areenan et al., | |
| 100 mg/kg | Rat heart | Weerateerangkul et al., | ||
| Ca2+ antagonists | 0.1–1 mg/ml | Rabbit intestines | Gilani et al., | |
| Likely acts via the NO pathways, | 80 mg dry extract/kg, once a day, for 5 days. | Rat aorta | El Bardai et al., | |
| Blocks L-type calcium channels | 1–30 μM of marrubenol (a component of | Endothelial denuded aortic rings | El-Bardai et al., | |
| Decreases endothelin, epinephrine and norepinephrine | 60 mg/kg | DOCA-salt-sensitive hypertensive rats | Veeramani et al., | |
| Increases eNOS expression | 0.5–50 mg/ml | Rat and guinea-pig aortic strips | Zamble ´ et al., | |
| Regulates sympathetic tone | 1–10 mg/kg | Rat isolated aorta | Lahlou et al., | |
| Increases NO | 0.1–10 g/l | Rat isolated thoracic aortic rings | Senejoux et al., | |
| Ameliorates lipidemia-induced endothelial dysfunction | 0.5 g/kg body weight | Rat isolated aortic rings | Amrani et al., | |
| Decreases ET-1 and Ang II levels | 100, 200, and 400 mg/kg | Renovascular hypertensive rats | Umar et al., | |
| Increases NO | 5.16 μg/ml | Rat carotid arterial rings | Kim et al., | |
| Increases NO | 3–30 μM | Rat isolated rat aorta | Shi et al., | |
| Antagonizes Ca2+ | 10–100 μM | Rat aortic smooth muscles | Wang et al., | |
| Increases NO | 1–100 μM | Rat isolated aortic rings | Xu et al., | |
| Antagonizes Ca2+ | 1–20 μM | Rabbit aortic rings | Taqvi et al., | |
| Increases NO | 10.7 μg/ml | Rat aorta | Raimundo et al., | |
| Regulates histamine receptors | ||||
| Increases NO | 100 and 200 (mg/kg) | Db/db mice with type 2 diabetes | Hwang et al., | |
| Increases NO | 81 μg/ml | Rat endothelial-intact aortic ring | Khonsung et al., | |
| Opens KATP channels | 1 mg/ml of the extract; | Rat thoracic aorta | Sun et al., | |
| Decreases Ang II levels | 6.25–25 mg/kg/day | 2K-1C rats | Cao et al., | |
| Reduces Ang II concentration | 0.2 mg/ml (of the plant's glycosides) | 2K-1C rats | Liu et al., | |
| Increases NO | 30 and 90 mg/kg | SHR | Chung et al., | |
| 0.3–3 mg/ml | Rat Isolated aorta | Ghayur and Gilani, | ||
| Guinea-pig atria | ||||
| Reduces BP and HR; unclear mechanism | 0.5–2 mg/animal | Rats | Tanira et al., | |
| Activates eNOS | 0.3–300 μg/ml | Rabbit isolated aortic rings | Beretta et al., | |
| Increases NO | 180 mg/ml | Rat Isolated aorta | Suresh Kumar et al., | |
| Increases NO | 75 μg/ml | Rat aortic rings | Monteiro et al., | |
| Regulates NO and ET-1 | 100 and 200 mg/kg | Rats with atherogenic diet | Sohn et al., | |
| Blocks Ca2+ channels | 3–30 mg/kg ( | Rats | Qian et al., | |
| Increases NO | 0.3–15 mg/ml | SHR | Phillips et al., | |
| Reduces ACE | 10 mg/kg | 2K-1C rats | Sharifi et al., | |
| Not clear | 0.15–1.05 mg/ml | Rat isolated aortic rings | Salahdeen and Murtala, | |
| Inhibits ACE | 30–300 mg/kg of hydroethanolic extract, or 25–100 mg/kg of semi-purified fraction | ACE activity assay (in serum from normotensive Wistar rats) | Gasparotto Junior et al., | |
| Increases NO | ||||
| Increases NO | 450 mg/kg/day | SHR | Goto et al., | |
| Increases NO | 0.39 and 0.4 mg/ml | Guinea-pig atria and rat aorta | Siddiqi et al., | |
| Regulates Ca2+ | 0.3–3 mg/ml | |||
| Increases NO | 60 mg/kg/day | Glucocorticoid-treated rats | Bachhav et al., | |
| Increases NO | 0.1–100 μM | L-NAME treated rats | Fu et al., |
Less commonly used antihypertensive plants with anti-inflammatory activity.
| Suppresses VCAM-1 (aortic endothelia) | 100 and 200 mg/kg/day | High fat-fed Sprague-Dawley rat thoracic aorta | Lee Y. J. et al., | |
| Decreases soluble (plasma) VCAM-1 | 2.1 g/day | Healthy humans | Koyama et al., | |
| Decreases NF-κB expression (mast cells) | 0.05–0.4 mg/ml | HMC-1 human mast cells | Kim et al., | |
| Decreases TNF- α and IL-6 (renal tissue) | 200 mg/kg | renovascular hypertensive rats | Kalaivani et al., | |
| Inhibits VCAM-1 and ET-1 activity (aortic endothelia) | 100 and 200 mg/kg/day | High fat/cholesterol-fed ApoE-deficient mice | Choi et al., | |
| Decreases iNOS expression (gastric mucosa) | 0.02 mL/g | Stress-induced gastric lesions in mice | An et al., | |
| Decreases NF-κB, TNF-α, and COX-2 (RAW 264.7 cells) | 0–250 μg/ml (aqueous ethanol) or 0–200 μg/ml (hexane) fractions | LPS-treated RAW 264.7 macrophages | Kiemer et al., | |
| Decreases expression of iNOS (RAW 264.7 cells) | 20 and 100 μM of lupenone or lupeol, respectively | LPS-treated RAW 264.7 macrophages | Jin et al., | |
| Attenuates IFN-γ and IL-2 (serum of rats) | 0.4 g of the plant per 100g of the animal weight | Rat model of autoimmune myocarditis | Zhao et al., | |
| Reduces LPS-induced NO, IL-1β, TNF-α, and IFN-γ (RAW 264.7 cells) | 100 μg/ml of each sub-fraction | LPS-stimulated RAW264.7macrophages | Kook et al., | |
| Reduces LPS-induced NO, IL-6, IL-1β, IL-8, or TNF-α (colon tissue or RAW 264.7 cells) | 100 mg/kg rhein (in mice) or 8–40 μM of different anthraquinones (in RAW264.7 cells) | Mice or RAW264.7 cells | Hu et al., | |
| Reduces expression of IL-6, VCAM-1, and ET-1 (pulmonary artery endothelia) | 0.5–2 mg/mL | Monocrotaline-induced pulmonary hypertension in rats | Zhang et al., | |
| Regulates NO and ET-1 (aortic endothelia) | 100 and 200 mg/kg | Rats with atherogenic diet | Sohn et al., | |
| Inhibits LPS-induced expression of PgE2, iNOS, and COX-2 (THP-1 monocytic cell line) | 100 μM of tetrandrine (a component of | THP-1 cells | Wu and Ng, | |
| Reduces LPS-induced levels of IL1β and TNFα (BV-2 microglia) | 0.1–1 μM of tetrandrine (a component of | BV-2 microglia | Dang et al., |
Less commonly used antihypertensive plants with antiproliferative activity.
| Arrests VSMCs at G0/G1 | 300 μg/ml | Rat vascular smooth muscles | Hou et al., | |
| Arrests VSMCs in G1 phase | 20–160 μg/ml | Mouse aortic smooth muscle cells | Suh et al., | |
| Inhibits hypoxia or TGF-β-induced proliferation | 0.5–0.2 mg/ml | Pulmonary arterial smooth muscle cells | Zhang et al., | |
| Inhibits Ang II-induced proliferation | 0.240 mg/ml of the plant's total saponins | Primary VSMCs from aorta of newborn calves | Li et al., |
Less commonly used antihypertensive plants with diuretic activity.
| Increases urine output and enhances Na+ and K+ excretion | 1, 3, and 10 mg/kg | Anesthetized rats | Gilani et al., | |
| Increases urine output and electrolyte excretion | 50–100 mg/kg | Rats | Navarro et al., | |
| Increases electrolyte excretion | 20 mg/kg | SHR | Maghrani et al., | |
| Increases urine volume and Na+ levels in serum (humans) and decreases SBP and DBP (in man) | 80 mg/kg (in rabbits) | Mild hypertensive patients and rabbits | Srividya and Periwal, | |
| Reduces aldosterone | 300 mg/kg ethanolic extract, 200 mg/kg purified fraction, 10 mg/kg isoquercitrin | SHR | Gasparotto Junior et al., | |
| Downregulates renal Na+/K+ pump | ||||
| Increases urine volume | ||||
| Increases urine volume | 200 mg/kg/day | L-NAME-treated rats | Bachhav et al., | |
| Increases urine volume, electrolyte excretion and glomerular filtration rate | 100, 200, and 400 mg/kg | Male Wistar rats | Jadhav et al., |
Less commonly used antihypertensive plants used in clinical trials.
| Double-blind, placebo-controlled | 92 | Mild hypertension | 70 mg/day ethanolic safflower extract | 12 weeks | No significant SBP or DBP decrease | 0.8/1 mmHg | Suzuki et al., | |
| Placebo-controlled trial | 20 | Stage 1 hypertension | 3 g cardamom powder (1.5 g capsule, twice a day) | 12 weeks | SBP and DBP decrease | 19/12 mmHg | Verma et al., | |
| Controlled trial | 50 | Mild hypertension | 4% tea leaf powder | 45 days | SBP and DBP decrease | 23.8/15.5 mmHg | Raja et al., |
Figure 1Epigenetic-driven hypertension could be ameliorated by consumption of herbs and other factors. Environmental and lifestyle factors such as diet (high fat and carbohydrate, low protein; minimal fruit, herb, and vegetable consumption), and Physical Activity (Lack of exercise—sedentary lifestyle) significantly affect DNA methylation, chromatin remodeling, and miRNA regulation. Herbal intervention can favorably modulate these epigenetic modifiers.